HQL · NYSE · Closed-end fund
abrdn Life Sciences Investors (HQL) Price, Holdings & Fees
abrdn Life Sciences Investors (HQL) closed at $1,079.53 on Oct 9, 2026, up 0.96% from the previous close of $1,069.28.
Share price, past year
1Y −13.26%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,079.53 |
| Sep 30, 2026 | $1,065.09 |
| Aug 31, 2026 | $1,070.37 |
| Jul 31, 2026 | $1,142.33 |
| Jun 30, 2026 | $1,198.37 |
| May 29, 2026 | $1,224.43 |
| Apr 30, 2026 | $1,146.11 |
| Mar 31, 2026 | $1,109.49 |
| Feb 27, 2026 | $1,180.95 |
| Jan 30, 2026 | $1,224.49 |
| Dec 31, 2025 | $1,177.38 |
| Nov 28, 2025 | $1,164.24 |
| Oct 31, 2025 | $1,184.35 |
Key statistics
- Expense ratio
- —
- Net assets
- $689.2M
- as of Jun 30, 2026
- Holdings
- 158
- as of Jun 30, 2026
- 52-week range
- $1,058.42 – $1,277.69
Holdings
abrdn Life Sciences Investors held 158 investments worth $689.25M as of Jun 30, 2026. Its largest holding was uniQure NV, at 3.77% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | uniQure NV | 3.77% | $25.99M |
| 2 | Insmed Inc | 3.22% | $22.19M |
| 3 | VeraDermics Inc | 3.06% | $21.07M |
| 4 | Personalis Inc | 3.00% | $20.67M |
| 5 | Argenx SE | 2.64% | $18.22M |
| 6 | Dyne Therapeutics Inc | 2.58% | $17.76M |
| 7 | Denali Therapeutics Inc | 2.46% | $16.93M |
| 8 | VERADERMICS, INC. | 1.95% | $13.44M |
| 9 | Abivax SA | 1.90% | $13.07M |
| 10 | Immunovant Inc | 1.89% | $12.99M |
| 11 | Tectonic Therapeutic Inc | 1.85% | $12.75M |
| 12 | Crinetics Pharmaceuticals Inc | 1.69% | $11.68M |
| 13 | Oruka Therapeutics Inc | 1.69% | $11.68M |
| 14 | Equillium Inc | 1.69% | $11.62M |
| 15 | NEUROVANCE MILESTONE INTEREST | 1.66% | $11.41M |
| 16 | Edgewise Therapeutics Inc | 1.56% | $10.73M |
| 17 | Axsome Therapeutics Inc | 1.54% | $10.64M |
| 18 | Xenon Pharmaceuticals Inc | 1.50% | $10.31M |
| 19 | Taysha Gene Therapies Inc | 1.48% | $10.19M |
| 20 | Praxis Precision Medicines Inc | 1.48% | $10.18M |
| 21 | EyePoint Inc | 1.47% | $10.16M |
| 22 | Shattuck Labs Inc | 1.42% | $9.76M |
| 23 | Summit Therapeutics Inc | 1.33% | $9.19M |
| 24 | BioCryst Pharmaceuticals Inc | 1.30% | $8.98M |
| 25 | Disc Medicine Inc | 1.29% | $8.89M |
Top 25 of 158 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 88.97% |
| Preferred stock | 6.63% |
| Derivatives | 2.66% |
| Cash and short-term investments | 1.34% |
| Bonds and other debt | 0.38% |
| Other asset-backed securities | 0.09% |
| Country | % of fund |
|---|---|
| United States | 82.47% |
| Netherlands | 8.60% |
| France | 2.50% |
| Canada | 2.04% |
| Cayman Islands | 1.26% |
| Ireland | 0.81% |
| British Virgin Islands | 0.79% |
| Switzerland | 0.65% |
| Denmark | 0.45% |
| Belgium | 0.32% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jun 30, 2026, abrdn Life Sciences Investors's total return was +26.85%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jun 30, 2026 | +12.04% |
| May 31, 2026 | +5.26% |
| Apr 30, 2026 | +7.56% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- abrdn Life Sciences Investors
- Ticker
- HQL
- Exchange
- NYSE
- Fund type
- Closed-end fund
- SEC CIK
- 0000884121
- Fractional shares
- Yes
Recent SEC filings
- Aug 28, 2026
- Jun 8, 2026
- Dec 8, 2025
- Jun 9, 2025
- Dec 9, 2024
- Jun 10, 2024
- Dec 11, 2023
- Sep 12, 2023
Frequently asked questions
What is HQL's price?
abrdn Life Sciences Investors (HQL) closed at $1,079.53 on Oct 9, 2026, up 0.96% from the previous close of $1,069.28.
What does HQL hold?
abrdn Life Sciences Investors held 158 investments worth $689.25M as of Jun 30, 2026. Its largest holding was uniQure NV, at 3.77% of the fund. Its five largest holdings were uniQure NV, Insmed Inc, VeraDermics Inc, Personalis Inc, Argenx SE.
How has HQL performed?
Over the 3 months to Jun 30, 2026, abrdn Life Sciences Investors's total return was +26.85%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 28, 2026). Prices are generated sample data for development. Data sources and disclosures